JDRF-funded researchers across the globe are currently testing artificial pancreas systems. Some clinical trials are inpatient, in which participants stay overnight or for a few days in a hospital or research clinic, while others take place in an outpatient setting. In both cases, a medical team carefully monitors the daily life of each trial volunteer […]
July 30, 2013 ― Boris P. Kovatchev, Ph.D., a pioneering researcher at the University of Virginia (UVA) and a leading player in the efforts to advance artificial pancreas technology, was honored by JDRF yesterday with the prestigious Gerold & Kayla Grodsky Basic Research Scientist Award. The annual award recognizes leadership and innovation in type 1 […]
Leading experts from industry, academia, and government came together in early April in Bethesda, MD, to discuss innovation in the development of an artificial pancreas at a workshop hosted by the National Institutes of Health, the Food and Drug Administration (FDA), and JDRF. Artificial pancreas systems will automate insulin delivery and likely other hormones in […]
Shared connections to type 1 diabetes (T1D) brought together more than 600 people at the recent JDRF Type 1 Diabetes Research Summit held in Washington, D.C. Hosted by the JDRF Capitol Chapter, this one-day event was filled with informative, easy-to-understand presentations by top T1D researchers. Attendees had the opportunity to hear directly from these top […]
Leading experts from industry, academia, and government came together the second week of April in Bethesda, MD, to discuss innovation in the development of an artificial pancreas system at a workshop hosted by the National Institutes of Health, the Food and Drug Administration (FDA), and JDRF. A commercially-viable artificial pancreas system would mimic the biological […]
“How is managing diabetes like navigating an airplane?” That may sound like the beginning of a bad joke, but the answer resulted in a promising innovation in T1D treatment in JDRF’s current research portfolio. Like many other parents of children with type 1 diabetes (T1D), Don Matheson is well versed in the latest research advances […]
Every day, JDRF leverages the expertise and innovation of distinguished researchers from across the globe to support research for life-changing treatments and ultimately a cure for type 1 diabetes (T1D). Our mission aims to serve everybody with T1D—at all ages and stages of the disease. Please enjoy reading about some of the most recent advances […]
The U.S. Food and Drug Administration (FDA) announced on November 9 the issuance of its final guidance for the development of artificial pancreas systems. The guidance incorporates nearly all of JDRF’s recommendations. This news represents a milestone victory for JDRF and the type 1 diabetes (T1D) community, as the technology is viewed by medical experts […]
A first-of-its-kind clinical pilot study has demonstrated the safety and feasibility of an artificial pancreas system in an outpatient, “real-world” setting. A second clinical study has shown that a hypoglycemia-hyperglycemia minimizer system can predict when blood-glucose levels are about to rise or fall and make appropriate adjustments in insulin delivery. These JDRF-supported studies represent critical steps on the path to a functional artificial pancreas for the benefit of people living with T1D.
JDRF-funded researchers have developed a formulation of liquid glucagon that remains stable and viable for long periods of time and thus may be usable in standard diabetes pumps. The research represents advancement toward the routine delivery of glucagon for people with T1D and may also facilitate the development of bihormonal closed-loop artificial pancreas systems.